Role of endogenous peroxisome proliferator-activated receptor-α (PPAR-α) ligands in the development of gut ischemia and reperfusion in mice

Shock

Volumn 25, Issue 1, 2006, Pages 17-22

  Muià, Carmelo ^a   Mazzon, Emanuela ^a   Crisafulli, Concetta ^a   Di Paola, Rosanna ^a   Genovese, Tiziana ^a   Caputi, Achille P ^a   Cuzzocrea, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

IL 1 ; Ligand; Myeloperoxidase activity; PPAR ; PPAR KO mice; SAO shock; TNF

Indexed keywords

INTERLEUKIN 1; LIGAND; PEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; ILEUM; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; REPERFUSION INJURY; SHOCK;

ANIMALS; ILEUM; INTERLEUKIN-1; LIGANDS; MICE; MICE, KNOCKOUT; PEROXIDASE; PPAR ALPHA; REPERFUSION INJURY; SHOCK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646381905     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000186930.95227.4f     Document Type: Article

References (36)

1. Lefer AM, Lefer DJ: Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 33:71-90, 1993.
2. Granger DN, Rutili G, Mccord JM: Superoxide radicals in feline intestinal ischemia. Gastroenterology 81:22-23, 1981.
3. Granger DN: Cell adhesion and migration. II. Leukocyte-endothelial cell adhesion in the digestive system. Am J Physiol 273:G982-G986, 1977.
4. Butcher EC: Leukocyte-endothelial cell adhesion as an active, multi-step process: a combinatorial mechanism for specificity and diversity in leukocyte targeting. Adv Exp Med Biol 323:181-194, 1992.
5. Lawrence MB, Springer TA: Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 65:859-873, 1991.
6. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240:889-895, 1988.
7. Moras D, Gronemeyer H: The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 10:384-391, 1998.
8. Murphy GJ, Holder JC: PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469-474, 2000.
9. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688, 1999.
10. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354-366, 1996.
11. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B: Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142:4195-4202, 2001.
12. Sher T, Yi HF, McBride OW, Gonzalez FJ: cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598-5604, 1993.
13. Ito H, Nakano A, Kinoshita M, Matsumori A: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 83:1715-1721, 2003.
14. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Caputi AP: WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock 22:340-346, 2004.
15. Zingarelli B, Yang Z, Hake PW, Denenberg A, Wong HR: Absence of endogenous interleukin 10 enhances early stress response during post-ischaemic injury in mice intestine. Gut 48:610-622, 2001.
16. Mullane KM, Kraemer R, Smith B: Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14:157-167, 1985.
17. Diaz-Granados N, Howe K, Lu J, McKay DM: Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 156:2169-2177, 2000.
18. Cuzzocrea S, Dugo L, Patel NS, Di Paola R, Cockerill GW, Genovese T, Thiemermann C: High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis. Shock 21:342-351, 2004.
19. 2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol 140:366-376, 2003.
20. Ito K, Shimada J, Kato D, Toda S, Takagi T, Naito Y, Yoshikawa T, Kitamura N: Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. Eur J Cardiothorac Surg 25:530-536, 2004.
21. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL: Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135-144, 2004.
22. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, Stewart KN, Mota-Filipe H, Cuzzocrea S, Thiemermann C: Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 23:267-276, 2003.
23. Okaya T, Lentsch AB: Peroxisome proliferator-activated receptor-alpha regulates postischemic liver injury. Am J Physiol Gastrointest Liver Physiol 286:G606-G612, 2004.
24. 2), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock 24:59-65, 2005.
25. Zingarelli B, Cook JA: Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23:393-399, 2005.
26. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB: The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705, 1997.
27. Amsaguine-Safir S, Bianchi A, Collet P, Huin-Schohn C, Jeanvoine A, Becuwe P, Kremarik-Bouillaud P, Domenjoud L, Keller JM, Schohn H, Dauca M: Induction of the expression of the peroxisome proliferator-activated receptor alpha (PPARalpha) by clofibrate in jerboa tissues. Microsc Res Tech 61:185-190, 2003.
28. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N: Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and activators in a tissue- and inducer-specific manner. J Biol Chem 27:16710-16714, 1998.
29. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T: Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101:545-551, 2003.
30. Gervois P, Vu-Dac N, Kleemann R, Kockx M, Dubois G, Laine B, Kosykh V, Fruchart JC, Kooistra T, Staels B: Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 276:33471-33477, 2001.
31. Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka I, Takahashi N, Kawakami R, Li Y, Takemura G, Fujiwara H, Garbers DL, Mochizuki S, Nakao K: Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 108:203-213, 2001.
32. Konturek PC, Duda A, Brzozowski T, Konturek SJ, Kwiecien S, Drozdowicz D, Pajdo R, Meixner H, Hahn EG: Activation of genes for superoxide dismutase, interleukin-1beta, tumor necrosis factor-alpha, and intercellular adhesion molecule-1 during healing of ischemia-reperfusion-induced gastric injury. Scand J Gastroenterol 35:452-463, 2000.
33. Cuzzocrea S, Rossi A, Serraino I, Di Paola R, Dugo L, Genovese T, Britti D, Sciarra G, De Sarro A, Caputi AP, Sautebin L: 5-lipoxygenase knockout mice exhibit a resistance to splanchnic artery occlusion shock. Shock 20:230-236, 2003.
34. Cuzzocrea S, Riley DP, Caputi AP, Salvemmi D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 53:135-159, 2001.
35. Cuzzocrea S, McDonald MC, Mazzon E, Filipe HM, Costantino G, Caputi AP, Thiemermann C: Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of splanchnic artery occlusion and reperfusion. Shock 14:150-156, 2000.
36. Cuzzocrea S, Mazzon E, Dugo L, Caputi AP, Aston K, Riley DP, Salvemini D: Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion. Br J Pharmacol 132:19-29, 2001.